P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study

Autor: Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman

Publikováno v: Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)

Externí odkaz: https://doaj.org/article/faf247927fb4430283d6619bc5ef7574

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

Autor: Eric Morand, Marilyn Pike, Joan T. Merrill, Ronald van Vollenhoven, Victoria P. Werth, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

Publikováno v: Arthritis and Rheumatology. John Wiley and Sons Ltd
Morand, E, Pike, M, Merrill, J T, van Vollenhoven, R, Werth, V P, Hobar, C, Delev, N, Shah, V, Sharkey, B, Wegman, T, Catlett, I, Banerjee, S & Singhal, S 2022, ' Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus : A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial ', Arthritis and Rheumatology . https://doi.org/10.1002/art.42391

Objective: To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE). Methods: Adults with active SLE were enrolled fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0335c0ff0d29a498d97920776fb7fa70
https://pure.amc.nl/en/publications/deucravacitinib-a-tyrosine-kinase-2-inhibitor-in-systemic-lupus-erythematosus(bd4a3699-bb65-45a4-8754-6c4571660aad).html

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

Autor: Nicholas A Chronos, Mark E Leimbach, Roger J. Laham, Roderic I. Pettigrew, Marilyn Pike, M. J. Whitehouse, Carl Yoshizawa, James E. Udelson, Michael Simons, Justin D. Pearlman

Publikováno v: Journal of the American College of Cardiology. 36(7):2132-2139

OBJECTIVESEvaluate the safety, tolerability and preliminary efficacy of intracoronary (IC) basic fibroblast growth factor (bFGF, FGF-2).BACKGROUNDFGF-2 is a heparin-binding growth factor capable of inducing functionally significant angiogenesis in an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ea9313c009ab6e2369b4e74c639daf3

Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

Autor: Marilyn Pike, Julie Krop, Beth Jonas, David J. Hunter, Timothy E. McAlindon, Eugene Y. Kissin

Publikováno v: BMC Musculoskeletal Disorders, Vol 11, Iss 1, p 232 (2010)
BMC Musculoskeletal Disorders

Background There are no proven therapies that modify the structural changes associated with osteoarthritis (OA). Preclinical data suggests that intra-articular recombinant human BMP-7 (bone morphogenetic protein-7) has reparative effects on cartilage

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ebbc56a0fa7144d4f46f74f64791681
https://doi.org/10.1186/1471-2474-11-232

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma

Autor: Marilyn Pike, Gerald Edelman, Wilson Edwards, Dale Ando, R Steven Paulson, Kieron J. Kowal, Joan M. Robbins, Janet Bruce, Dee Wynne, Nadine Ognoskie, James Merritt, John Nemunaitis, Timothy Fong

Publikováno v: Cancer gene therapy. 6(4)

Background: Interferon-γ (IFN-γ) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a regression of established tumors in animal models. The purpose of this trial was to det

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f711bedc3fde2f9d8fefb985f7b8491
https://pubmed.ncbi.nlm.nih.gov/10419050